Transient treatment with CDK inhibitors eliminates proliferative potential even when their abilities to evoke...

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• Small molecule CDK inhibitors exhibit toxicity towards cancer cells.
• CDK inhibition leads to depletion of anti-apoptotic proteins, Chk1, DNA damage, and apoptosis.

Purpose of the Study:

• To determine which phenomena are essential for CDK inhibitors' anti-proliferative effects.
• To investigate the necessity of apoptosis, DNA damage, and protein depletion for CDK inhibitor efficacy.

Main Methods:

• Treatment of osteosarcoma cells with CDK2-specific and CDK7/9-specific inhibitors.
• Blocking apoptosis and overcoming DNA damage induction.
• Utilizing siRNA to suppress Mcl-1 and XIAP protein levels.
• Assessing biomarkers of cell cycle progression.

Main Results:

• 24-hour CDK inhibitor treatment eliminated proliferative potential, even when apoptosis was blocked and DNA damage was overcome.
• Loss of proliferative potential correlated with irreversible suppression of cell cycle progression biomarkers.
• CDK inhibitors reduced Mcl-1 and XIAP levels, but their suppression alone did not induce cell death.
• Many CDK inhibitors showed delayed or ineffective suppression of CDK/cyclin complexes at proliferation-blocking doses, suggesting potential CDK7 inhibition.

Conclusions:

• Irreversible suppression of cell cycle progression biomarkers is the key mechanism for CDK inhibitors' anti-proliferative effects.
• Apoptosis and DNA damage are not strictly necessary for CDK inhibitors to reduce proliferation.
• The reduction of anti-apoptotic proteins Mcl-1 and XIAP by CDK inhibitors does not directly cause cell death in these osteosarcoma cells.